This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) before stem cell transplantation. The data showed that pembrolizumab was effective and safe with manageable side effects in these patients.

This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the overall survival in these patients.

This study investigated the effects of foot-ankle therapeutic exercises on daily physical activity and gait (walking) speed in people with diabetic peripheral neuropathy (DPN). The data showed that at 12 weeks, these exercises led to improvements in fast walking speeds and quality of life compared to usual care.

This study assessed the effectiveness and safety of adding dorzagliatin (HMS552) to metformin therapy in patients with type 2 diabetes (T2D) with inadequately controlled blood glucose (sugar) while using metformin (Glucophage) alone. The data showed effective blood glucose control, good tolerance, and safety in patients treated with dorzagliatin and metformin.

This study evaluated the effectiveness and long-term safety of dorzagliatin in patients with type 2 diabetes (T2D) without previous antidiabetic treatment. The authors concluded that dorzagliatin blood glucose (sugar) levels with no serious side effects in these patients. 

This study analyzed the safety and effectiveness of dapagliflozin (Farxiga) in patients with type 2 diabetes (T2D) across different ranges of baseline systolic blood pressure (SBP; blood pressure when the heart beats). The data suggested that dapagliflozin reduced the risk of hospitalization for heart failure (HHF) and kidney-related outcomes and was safe for use across different levels of SBP without causing an increase in short-term (acute) kidney injury, dehydration, or amputations in patients.

This study examined the effect of icosapent ethyl (IPE; Vascepa) on major cardiovascular events (MACEs) in statin-treated patients that had previous heart attacks (myocardial infarction; MI). The data showed that patients treated with IPE had large and significant reductions in MACEs.

This review analyzed the effectiveness and safety of nutrient supplements for the control of blood glucose and insulin resistance in patients with type 2 diabetes (T2D). The authors concluded that there is currently a lack of sufficient clinical evidence to support the use of nutrient supplements for blood glucose control and improved insulin resistance in these patients.

This study compared the effectiveness and safety of an early and a delayed invasive strategy (IS) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). The data showed that there were no significant differences in the risk of death, heart attacks, stroke rates, major bleeding, or revascularization between early and delayed IS. Early IS significantly reduced the risk of recurrent ischemia and length of hospital stay in these patients.

This study examined the effects of consuming soymilk and probiotics on risk factors related to heart and blood vessel diseases in patients with type 2 diabetes (T2D). The study showed that the consumption of soymilk with probiotics might improve cardiovascular (CV) risk factors in these patients.